High Survivin Levels Predict Poor Clinical Response to Infliximab Treatment in Patients with Rheumatoid Arthritis
(2012) In Seminars in Arthritis and Rheumatism 41(5). p.652-657- Abstract
- Objective: To evaluate if the measurement of survivin in the blood of patients with rheumatoid arthritis (RA) undergoing infliximab treatment has predictive value for treatment response. Methods: The study included 87 consecutive RA patients (age 24-89 years, disease duration 18-526 months) treated with regular infusions of influximab. Survivin levels were measured by enzyme-linked immunosorbent assay and evaluated in relation to the total dose of infliximab, disease activity (DAS28), response to infliximab treatment (change in DAS28 > 1.2), and radiographic damage (vdH-Sharp score). Results: Thirty-seven percent of patients were survivin-positive (survivin > 0.9 ng/mL) and showed severe radiographic damage at the start of infliximab... (More)
- Objective: To evaluate if the measurement of survivin in the blood of patients with rheumatoid arthritis (RA) undergoing infliximab treatment has predictive value for treatment response. Methods: The study included 87 consecutive RA patients (age 24-89 years, disease duration 18-526 months) treated with regular infusions of influximab. Survivin levels were measured by enzyme-linked immunosorbent assay and evaluated in relation to the total dose of infliximab, disease activity (DAS28), response to infliximab treatment (change in DAS28 > 1.2), and radiographic damage (vdH-Sharp score). Results: Thirty-seven percent of patients were survivin-positive (survivin > 0.9 ng/mL) and showed severe radiographic damage at the start of infliximab treatment compared with survivin-negative (P = 0.027). Patients with high survivin levels were unlikely to respond to infliximab treatment (OR 4.02 [1.22-14.61], P = 0.022) and achieve remission (OR 4.32[1.01-30.11], P = 0.048) compared with patients with low survivin levels. Conclusions: High survivin levels are associated with severe radiographic damage at the start of treatment and a poor response to infliximab. Survivin measurement should be considered an additional tool for aiding the selection and follow-up of antirheumatic treatment. (C) 2012 Elsevier Inc. All rights reserved. Semin Arthritis Rheum 41:652-657 (Less)
Please use this url to cite or link to this publication:
https://lup.lub.lu.se/record/2571145
- author
- Isgren, Anniella ; Forslind, Kristina LU ; Erlandsson, Malin ; Axelsson, Carl ; Andersson, Sofia ; Lund, Anneli and Bokarewa, Maria
- organization
- publishing date
- 2012
- type
- Contribution to journal
- publication status
- published
- subject
- keywords
- rheumatoid arthritis, infliximab, surviving, treatment
- in
- Seminars in Arthritis and Rheumatism
- volume
- 41
- issue
- 5
- pages
- 652 - 657
- publisher
- W.B. Saunders
- external identifiers
-
- wos:000302928900003
- scopus:84859434524
- pmid:22035627
- ISSN
- 0049-0172
- DOI
- 10.1016/j.semarthrit.2011.08.005
- language
- English
- LU publication?
- yes
- id
- 3f794540-eac9-4154-b963-7dad6c6a8e6d (old id 2571145)
- date added to LUP
- 2016-04-01 10:35:32
- date last changed
- 2022-03-12 07:20:30
@article{3f794540-eac9-4154-b963-7dad6c6a8e6d,
abstract = {{Objective: To evaluate if the measurement of survivin in the blood of patients with rheumatoid arthritis (RA) undergoing infliximab treatment has predictive value for treatment response. Methods: The study included 87 consecutive RA patients (age 24-89 years, disease duration 18-526 months) treated with regular infusions of influximab. Survivin levels were measured by enzyme-linked immunosorbent assay and evaluated in relation to the total dose of infliximab, disease activity (DAS28), response to infliximab treatment (change in DAS28 > 1.2), and radiographic damage (vdH-Sharp score). Results: Thirty-seven percent of patients were survivin-positive (survivin > 0.9 ng/mL) and showed severe radiographic damage at the start of infliximab treatment compared with survivin-negative (P = 0.027). Patients with high survivin levels were unlikely to respond to infliximab treatment (OR 4.02 [1.22-14.61], P = 0.022) and achieve remission (OR 4.32[1.01-30.11], P = 0.048) compared with patients with low survivin levels. Conclusions: High survivin levels are associated with severe radiographic damage at the start of treatment and a poor response to infliximab. Survivin measurement should be considered an additional tool for aiding the selection and follow-up of antirheumatic treatment. (C) 2012 Elsevier Inc. All rights reserved. Semin Arthritis Rheum 41:652-657}},
author = {{Isgren, Anniella and Forslind, Kristina and Erlandsson, Malin and Axelsson, Carl and Andersson, Sofia and Lund, Anneli and Bokarewa, Maria}},
issn = {{0049-0172}},
keywords = {{rheumatoid arthritis; infliximab; surviving; treatment}},
language = {{eng}},
number = {{5}},
pages = {{652--657}},
publisher = {{W.B. Saunders}},
series = {{Seminars in Arthritis and Rheumatism}},
title = {{High Survivin Levels Predict Poor Clinical Response to Infliximab Treatment in Patients with Rheumatoid Arthritis}},
url = {{http://dx.doi.org/10.1016/j.semarthrit.2011.08.005}},
doi = {{10.1016/j.semarthrit.2011.08.005}},
volume = {{41}},
year = {{2012}},
}